Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) have been assigned an average recommendation of “Reduce” from the twelve brokerages that are currently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a sell rating, seven have issued a hold rating and one has given a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $8.20.
FULC has been the topic of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Thursday, October 15th. Wall Street Zen raised Fulcrum Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 14th.
Read Our Latest Analysis on FULC
Hedge Funds Weigh In On Fulcrum Therapeutics
A number of hedge funds have recently made changes to their positions in the business. State of Wyoming acquired a new stake in shares of Fulcrum Therapeutics in the 3rd quarter valued at $35,000. ProShare Advisors LLC bought a new stake in shares of Fulcrum Therapeutics in the 3rd quarter worth about $41,000. China Universal Asset Management Co. Ltd. increased its position in shares of Fulcrum Therapeutics by 31.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,921 shares of the company’s stock worth $52,000 after purchasing an additional 3,316 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Fulcrum Therapeutics by 25.0% during the 1st quarter. The Manufacturers Life Insurance Company now owns 16,102 shares of the company’s stock worth $124,000 after purchasing an additional 3,219 shares in the last quarter. Finally, Westshore Wealth LLC acquired a new stake in shares of Fulcrum Therapeutics during the 1st quarter worth about $130,000. Institutional investors and hedge funds own 89.83% of the company’s stock.
Fulcrum Therapeutics Stock Down 0.5%
NASDAQ:FULC opened at $3.69 on Friday. The business’s 50-day moving average price is $3.72 and its 200 day moving average price is $5.38. The firm has a market cap of $281.85 million, a P/E ratio of -3.55 and a beta of 2.82. Fulcrum Therapeutics has a 52-week low of $2.83 and a 52-week high of $15.74.
Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.11). Sell-side analysts expect that Fulcrum Therapeutics will post -0.67 EPS for the current year.
Fulcrum Therapeutics Company Profile
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. It develops medicines for genetically defined diseases, with research focused on changing gene expression to address the underlying causes of illness. The company’s work has included programs for sickle cell disease and facioscapulohumeral muscular dystrophy, a rare genetic muscle disorder. Its research has explored approaches such as influencing hemoglobin production and modifying disease-related gene activity.
See Also
- Five stocks we like better than Fulcrum Therapeutics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
